Cancer gene therapy: Strategies and clinical trials

Cellular and Molecular Biology

Volumn 51, Issue 1, 2005, Pages 23-36

  Prados, J ^a   Melguizo, C ^b   Boulaiz, H ^a   Marchal, J A ^c   Aranega A ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF ALMERÍA   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

Author keywords

Angiogenesis; Apoptosis; Cancer; Gene therapy; Suicide gene; Suppressor gene

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (AZIRIDIN 1 YL) 2,4 HIDROXYLAMINO 2 NITROBENZAMIDE; 6 THIOXANTHINE; 6 THIOXANTHINE MONOPHOSPHATE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACICLOVIR; ADENOVIRUS VECTOR; BACTERIAL PROTEIN; BETA 2 MICROGLOBULIN; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOSINE DEAMINASE; DOXIFLURIDINE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; HLA B7 ANTIGEN; IFOSFAMIDE; IRINOTECAN; LIPOSOME; NUCLEOTIDE DERIVATIVE; PHOSPHORAMIDE MUSTARD; PRODRUG; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; RECOMBINANT PROTEIN; RETROVIRUS VECTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; FEVER; GENE MUTATION; GENE TRANSFER; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; INFLAMMATION; KIDNEY SARCOMA; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESOTHELIOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CARCINOMA; PANCREAS CANCER; PROGNOSIS; PROMOTER REGION; PROSTATE CANCER; REVIEW; SUICIDE GENE; SUICIDE GENE THERAPY; TARGET CELL DESTRUCTION; THROMBOCYTOPENIA; TUMOR CELL CULTURE; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VOMITING;

ANIMALS; APOPTOSIS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASMS; ONCOGENE PROTEINS;

ADENOVIRIDAE; ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 30744454265     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: None     Document Type: Review

References (163)

1. Advani, R., Peethambaram, P., Lum, B.L., Fisher, G.A., Hartmann, L., Long, H.J Halsey, J., Holmlund, J.T., Dorr, A. and Sikic, B.I., A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 2004, 100: 321-326.
2. Anderson, L.M., Krotz, S., Weitzman, S.A. and Thimmapaya, B., Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. Cancer Gene Ther. 2000, 7: 845-852.
3. Anlezark, G.M., Melton, R.G., Sherwood, R.F., Coles, B., Friedlos, F. and Knox, R.J., The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification and properties of a nitroreductase enzyme from Escherichia coli a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 1992, 44: 2289-2295.
4. Arienti, F., Belli, F., Napolitano, F., Sule-Suso, J., Mazzocchi, A., Gallino, G.F., Cattelan, A., Sanantonio, C., Rivoltini, L., Melani, C., Colombo, M.P., Cascinelli, N., Maio, M. and Parmiani, G., Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 1999, 10: 2907-2916.
5. Austin, E.A. and Hubert, B.E., A first step in the development of gene therapy for colorectal cacinoma: cloning, sequencing and expression of Escherichia coli cytosine daminase. Mol. Pharmacol. 1993, 43: 380-387.
6. Belldegrun, A., Tso, C.L., Zisman, A., Naitoh, J., Said, J., Pantuck, A.J., Hinkel, A, deKernion, J. and Figlin, R., Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum. Gene Ther. 2001, 12: 883-892.
7. Bishop, M.R., Iversen, P.L., Bayever, E., Sharp, J.G., Greiner, T.C., Copple, B.L., Ruddon, R., Zon, G., Spinolo, J., Arneson, M., Armitage, J.O. and Kessinger, A., Phase I trial of an antisense oligonucleotide OL(1) p53 in hematologic malignancies. J. Clin. Oncol. 1996, 14: 1320-1326.
8. Block, A., Chen, S.H., Kosai, K.I., Finegold, M. and Woo, S.L.C., Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: Regression of hepatic metastasis of pancreatic tumors. Pancreas 1997, 15: 25-34.
9. Block, A., Freund, C.T., Chen, S.H., Nguyen, K.P., Finegold, M., Windler, E. and Woo, S.L.C., Gene therapy of metastatic colon carcinoma: regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase. Cancer Gene Ther. 2000, 7: 438-445.
10. Boulaiz, H., Prados, J., Melguizo, C., García, A., Marchal, J.A., Carrillo, E., Ramos, J.L. and Aranega, A., Inhibition of cell proliferation and apoptosis induction in human melanoma MCF7 cell line by Gef gene. Br. J. Cancer 2003, 89: 192-198.
11. Boulaiz, H., Prados, J., Marchal, J.A., García, A., Alvarez, L., Melguizo, C., Carrillo, E., Ramos, J.L. and Aranega, A., Transfection of MS-36 melanoma cells with Gef gene inhibits proliferation and induce modulation of cell cycle. Cancer Science 2003, 94: 564-568.
12. Bouvet, M., Bold, R.J., Lee, J., Evans, D.B., Abbruzzese, J.L., Chiao, P.J., McConkey, D.J., Chandra, J., Chada, S., Fang, B. and Roth, J.A., Adenovirus-mediated wild-type p53 tumour suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann. Surg. Oncol. 1998, 5: 681-688.
13. Cao, G., Kuriyama, S., Gao, J., Kikukawa, M., Cui, L., Nakatani, T., Zhang, X., Tsujinoue, H., Pan, X., Fukui, H. and Qi, Z., Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter. Gene Ther. 1999, 6: 83-90.
14. Chang, A.E., Li, Q., Bishop, D.K., Normolle, D.P., Redman, B.D. and Nickoloff, B.J., Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum. Gene Ther. 2000, 11: 839-850.
15. Chen, S.H., Shine, H.D., Goodman, J.C., Grossman, R.G. and Woo, S.L., Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 1994, 91: 3054-3057.
16. Chen, L. and Waxman, D.J., Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 1995, 55: 581-589.
17. Chen, S.H., Chen, X.H.L., Wang, T.B., Kosai, K.I., Finegold, M.J., Rich, S.S. and Woo, S.L.C., Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. Natl. Acad. Sci. USA 1995, 92: 2577-2581.
18. Chen, L., Waxman, D.J., Chen, D.S. and Kufe, D.W., Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 1996, 56: 1331-1340.
19. Chen, H.X., Marshall, J.L., Ness, E., Martin, R.R., Dvorchik, B., Rizvi, N., Marquis, J., McKinlay, M., Dahut, W. and Hawkins, M.J., A safety and pharmaco-kinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumours. Clin. Cancer Res. 2000, 6: 1259-1266.
20. Cheon, J., Ko, S.C., Gardner, T.A., Shirakawa, T., Gotoh, A., Kao, C. and Chung, L.W., Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther. 1997, 4: 359-365.
21. Clayman, G.L., Frank, D.K., Bruso, P.A. and Goepfert, H., Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin. Cancer Res. 1999, 5:1715-22.
22. Cortés, M.L., Felipe, P., Martín, V., Hughes M.A., and Izquierdo, M., Successful use of a plant gene in the treatment of cancer in vivo. Gene Ther. 1998, 5: 1499-1507.
23. Crystal, R.G., Hirschowitz, E., Lieberman, M., Daly, J., Kazam, E., Henschke, C., Yankelevitz, D., Kemeny, N., Silverstein, R., Ohwada, A., Russi, T., Mastrangeli, A., Sanders, A., Cooke, J. and Harvey, B.G., Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum. Gene Ther. 1997, 8: 985-1001.
24. Culver, K.W., Ram, Z., Walbridge, S., Ishii, H., Oldfield, E.H. and Blaese, R.M., In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumor. Science 1992, 256: 1550-1552.
25. Cunningham, C.C., Holmlund, J.T., Schiller, J.H., Geary, R.S., Kwoh, T.J., Dorr, A. and Nemunaitis, J., A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 2000, 6: 1626-1631.
26. Czubayko, F., Downing, S.G., Hsieh, S.S., Goldstein, D.J., Lu, P.Y., Trapnell, B.C. and Wellstein, A., Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Ther. 1997, 4: 943-949.
27. Dalgleish, A., The case for therapeutic vaccines. Melanoma Res. 1996, 6: 5-10.
28. Denny, W.A., Prodrugs for gene-directed enzyme-prodrug therapy (Suicide gene therapy). J. Biomed. Biotechnol. 2003, 1: 48-70.
29. Dohring, C., Angman, L., Spagnoli, G. and Lanzavecchia, A., T-helper and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int. J. Cancer 1994, 57: 754-759.
30. Dorai, T., Perlman, H., Walsh, K., Shabsigh, A., Goluboff, E.T., Olsson, C.A. and Buttyan, R., A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int. J. Cancer 1999, 82: 846-852.
31. Earnshaw, D.J. and Gait, M.J., Hairpin ribozyme cleavage catalyzed by aminoglycoside antibiotics and the polyamine spermine in the absence of metal ions. Nucleic. Acids Res. 1998, 26: 5551-5561.
32. Ehlken, H., Schadendorf, D. and Eichmuller, S., Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells. Int. J. Cancer 2004, 108: 307-313.
33. Erbs, P. and Regulier, E., In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 2000, 60: 3813-3822.
34. Evan, G. and Littlewood, T., A matter of life and cell death. Science 1998, 281: 1317-1322.
35. Evoy, D., Hischowitz, E.A., Naama, H.A,, Li, X.K., Crystal, R.G., Daly, J.M. and Lieberman, M.D., In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J. Surg. Res. 1997, 69: 226-231.
36. Farzaneh, F., Trefzer, U., Sterry, W. and Walden, P., Gene therapy of cancer. Immunol. Today 1998, 19: 294-296.
37. Feldman, A.L., Restifo, N.P., Alexander, H.R., Bartlett, D.L., Hwu, P., Seth, P. and Libutti, S.K., Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res. 2000, 60: 1503-1506.
38. Frazier, M.L., Gene expression in pancreas adenocarcinoma. Ann. N.Y. Acad. Sci. 1999, 880: 1-4.
39. Freeman, S.M., The treatment of ovarian cancer with a gene modified cancer vaccine. Hum. Gene Ther. 1995, 6: 927-939.
40. Freeman, S.M., Whartenby, K.A., Freeman, J.L., Abboud, C.N. and Marrogi, A.J., In situ use of suicide genes for cancer therapy. Semin. Oncol. 1996, 23: 31-35.
41. Freytag, S.O., Khil, M., Stricker, H., Peabody, J., Menon, M., DePeralta-Venturina, M., Nafziger, D., Pegg, J., Paielli, D., Brown, S., Barton, K., Lu, M., Aguilar-Cordova, E. and Kim, J.H., Phase I study of replication competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002, 62: 4968-4976.
42. Freytag, S.O., Stricker, H., Pegg, J., Paielli, D., Pradhan, D.G., Peabody, J., DePeralta-Venturina, M., Xia, X., Brown, S., Lu, M. and Kim, J.H., Phase I study of replication competent adenovirus-mediated double-suicide gene therapy in combination with conventional dose three dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 2003, 63: 7497-7506.
43. Gadi, V.K., Alexander, S.D., Kudlow, J.E., Allan, P., Parker, W.B. and Sorscher, E.J., In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther. 2000, 7: 1738-1743.
44. Galanis, E., Hersh, E.M., Stopeck, A.T., Gonzalez, R., Burch, P., Spier, C., Akporiaye, E.T., Rinehart, J.J., Edmonson, J., Sobol, R.E., Forscher, C., Sondak, V.K., Lewis, B.D., Unger, E.C., O'Driscoll, M., Selk, L. and Rubin, J., Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J. Clin. Oncol. 1999, 17: 3313-3323.
45. Garcia-Lora, A., Algarra, I. and Garrido, F., MHC class I antigens, immune surveillance and tumor immune escape. J. Cell Physiol. 2003, 195: 346-355.
46. Germano, I.M., Fable, J., Gultekin, S.H. and Silvers, A., Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J. Neurooncol. 2003, 65: 279-289.
47. Gilly, F.N., Beaujard, A., Bienvenu, J., Lenoir, V.T., Glehen, O., Thouvenot, D., Malcus, C., Favrot, M., Dumontet, C., Lomhard-Bohas, C., Garbit, F., Gueugniaud, P.Y., Vignal, J., Aymard, M., Moulin, F.T., Roos, M., Pavirani, A. and Courtney, M., Gene therapy with AdV-IL-2 in unresectable digestive cancer: Phase I-II study, intermediate report. Hepatogastroenterology 1999, 46: 1268-1273.
48. Gleich, L.L., Gluckman, J.L., Armstrong, S., Biddinger, P.W., Miller, M.A., Balakrishnan, K., Wilson, K.M., Saavedra, H.I. and Stambrook, P.J., Alloantigen gene therapy for squamous cell carcinoma of the head and neck - Results of a phase 1 trial. Arch. Otolaryngol. Head Neck Surg. 1998, 124: 1097-1104.
49. Goldman, C.K., Kendall, R.L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G.Y., Siegal, G.P., Mao, X.Z., Bett, A.J., Huckle, W.R., Thomas, K.A. and Curiel, D.T., Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. USA 1998, 95: 8795-8800.
50. Gotoh, A., Ko, S.C., Shirakawa, T., Cheon, J., Kao, C.H., Miyamoto, T., Gardner, T.A., Ho, L.J., Cleutjens, C.B.J., Trapman, J., Graham, F.L. and Chung, L.W.K., Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J. Urol. 1998; 160: 220-229.
51. Griffith, T.S., Anderson, R.D., Davidson, B.L., Williams, R.D. and Ratliff, T.L., Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J. Immunol. 2000, 165: 2886-2894.
52. Grove, J.I., Searle, P.F., Weedon, S.J., Green, N.K., McNeish, I.A. and Kerr, D.J., Virus-directed enzyme prodrug therapy using CB1954. Anticancer Drug Des. 1999, 14: 461-472.
53. Hall, S.J., Sanford, M.A., Atkinson, G. and Chen, S.H., Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res. 1998, 58: 3221-3225.
54. Hall, M.C., Li, Y., Pong, R.C., Ely, B., Sagalowsky, A.I. and Hsieh, J.T., The growth inhibitory effect of p21 adenovirus on human bladder cancer cells. J. Urol. 2000, 163: 1033-1038.
55. Hamstra, D.A. and Rehemtulla, A., Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. Hum. Gene Ther. 1999; 10: 235-248.
56. Hanahan, D. and Folkman, J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86: 353-364.
57. Hapke, D.M., Stegmann, A.P.A. and Mitchell, B.S., Retroviral transfer of deoxicytidine kinase into tumor cell line enhanes nucleoside toxicity. Cancer Res. 1996, 56: 2343-2347.
58. Harris, S.R. and Thorgeirsson, U.P., Tumor angiogenesis: biology and therapeutic prospects. In Vivo 1998, 12: 563-570.
59. Hasenburg, A., Tong, X.W., Rojas-Martinez, A., Nyberg-Hoffman, C., Kieback, C.C., Kaplan, A., Kaufman, R.H., Ramzy, I., Aguilar-Cordova, E. and Kieback, D.G., Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther. 2000, 7: 839-844.
60. Herman, J.R., Adler, H.L., Aguilar-Cordova, E., Rojas-Martinez, A., Woo, S., Timme, T.L., Wheeler, T.M., Thompson, T.C. and Scardino, P.T., In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum. Gene Ther. 1999, 10: 1239-1249.
61. Hirano, T., Kaneko, S., Kaneda, Y., Saito, I., Tamaoki, T., Furuyama, J., Tamaoki, T., Kobayashi, K., Ueki, T. and Fujimoto, J., HVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice. Gene Ther. 2001, 8: 80-83.
62. Hughes, B.W., Wells, A.H., Bebok, Z., Gadi, V.K., Garver, R.I,, Parker, W.B. and Sorscher, E.J., Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 1995, 55: 3339-3345.
63. Hunt, K.K., Deng, J., Liu, T.J., Wilson-Heiner, M., Swisher, S.G., Clayman, G. and Hung, M.C., Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res. 1997, 57: 4722-4726.
64. Hyer, M.L., Voelkel-Johnson, C., Rubinchik, S., Dong, J. and Norris, J.S., Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol. Ther. 2000, 2: 348-358.
65. Ido, A., Nakata, K., Kato, Y., Nakao, K., Murata, K., Fujita, M., Ishii, N., Tamaoki, T., Shiku, H. and Nagataki, S., Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res. 1995, 55: 3105-3109.
66. Ishiwata, N., Inase, N., Fujie, T., Tamaoka, M. and Yoshizawa, Y., Suicide gene therapy using keratin 19 enhancer and promoter in malignant mesothelioma cells. Anticancer Res. 2003, 23: 1405-1409.
67. Izquierdo, M., Martín, V., Felipe, P., Izquierdo, J.M., Pérez-Higueras, A., Cortés, M.L., Paz, J.F, Isla, A. and Blázquez, M.G., Human malignant brain tumor response to Herpes simplex thimidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther. 1996, 3: 491-495.
68. Jaffe, E.M., Hruban, R.H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P.R., Goemann, M., Coleman, J., Grochow, L., Donehower, R.C., Lillemoe, K.D., O'Reilly, S., Abrams, R.A., Pardoll, D.M., Cameron, J.L. and Yeo, C.J., Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activations. J. Clin. Oncol. 2001, 19: 145-156.
69. Jansen, B., Schlagbauer-Wadl, H., Brown, B.D., Bryan, R.N., van Elsas, A., Muller, M., Wolff, K., Eichler, H.G. and Pehamberger, H., bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 1998, 4: 232-234.
70. Jen, K.Y. and Gewirtz, A.M., Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies. Stem Cells 2000, 18: 307-319.
71. Kanai, F., Lan, K.H., Shiratori, Y., Tanaka, T., Ohashi, M., Okudaira, T., Yoshida, Y., Wakimoto, H., Hamada, H., Nakabayashi, H., Tamaoki, T. and Omata, M., In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 1997, 57: 461-465.
72. Kievit, E., Bershad, E., Ng, E., Sethna, P., Dev, I., Lawrence, T.S. and Rehemtulla, A., Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 1999, 59: 1417-1421.
73. Klatzmann, D., Cherin, P., Bensimon, G., Boyer, O., Coutellier, A., Charlotte, F., Boccaccio C., Salzmann, J.L. and Herson, S., A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum. Gene Ther. 1998, 9: 2585-2594.
74. Klatzmann, D., Valery, C.A., Bensimon, G., Marro, B., Boyer, O., Mokhtari, K., Diquet, B, Salzmann, J.L. and Philippon, J., A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther. 1998, 9: 2595-2604.
75. Knox, R.J., Friedlos, F., Marchbank, T. and Roberts, J.J., Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem. Pharmacol. 1991, 42: 1691-1697.
76. Knudson, A.G., Cancer genetics. Am. J. Med. Genet. 2002, 111: 96-102.
77. Koeneman, K.S., Kao, C., Ko, S.C., Yang, L., Wada, Y., Kallmes, D.F., Gillenwater, J.Y., Zhau, H.E., Chung, L.W. and Gardner, T.A., Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J. Urol. 2000, 18: 102-110.
78. Koshida, K., Kawami, H., Yagamuchi, Y., Kuniyasu, H., Nishiyama, M. and Hirai, T., Retrovirally transmitted gene therapy for gastric carcinoma using herpes simplex virus thymidine kinase gene. Cancer 1995, 75: 1467-1471.
79. Kubo, H., Gardner, T.A., Wada, Y., Koeneman, K.S., Gotoh, A., Yang, L., Kao, C., Lim, S.D., Amin, M.B., Yang, H., Black, M.E., Matsubara, S., Nakagawa, M., Gillenwater, J.Y., Zhau, H.E. and Chung, L.W., Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum. Gene Ther. 2003, 14: 227-241.
80. Lang, F.F., Bruner, J.M., Fuller, G.N., Aldape, K., Prados, M.D., Chang, S., Berger, M.S., McDermott, M.W., Kunwar, S.M., Junck, L.R., Chandler, W., Zwiebel, J.A., Kaplan, R.S. and Yung, W.K., Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol. 2003, 21: 2508-2518.
81. Latham, J.P., Searle, P.F., Mautner, V. and James, N.D., Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 2000, 60: 334-341.
82. Li, X.Y., Marani, M., Yu, J., Nan, B.C., Roth, J.A., Kagawa, S., Fang, B.L., Denner, L. and Marcelli, M., Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer. Cancer Res. 2001, 61: 186-191.
83. Maio, M., Fonsatti, E., Lamaj, E., Altomonte, M., Cattarossi, I., Santantonio, C., Melani, C., Belli, F., Arienti, F., Colombo, M.P. and Parmiani, G., Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol. Immunother. 2002, 51: 9-14.
84. Marcucci, G., Byrd, J.C., Dai, G., Klisovic, M.I., Kourlas, P.J., Young, D.C., Cataland, S.R., Fisher, D.B., Lucas, D., Chan, K.K., Porcu, P., Lin, Z.P., Farag, S.F., Frankel, S.R., Zwiebel, J.A., Kraut, E.H., Balcerzak, S.P., Bloomfield, C.D., Grever, M.R. and Caligiuri, M.A., Phase I and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003, 101: 425-432.
85. Mastrangelo, M.J., Maguire, H.C, Eisenlohr, L.C., Laughlin, C.E., Monken, C.E., McCue, P.A., Kovatich, A.J. and Lattime, E.C., Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999, 6: 409-422.
86. Matsukura, N., Hoshino, A., Igarashi, T., Hasegawa, H., Okino, T., Onda, M., Iijima, O., Akiyama, K., Goto, T., Takubo, K., Suzuki, S. and Shimada, T., In situ gene transfer and suicide gene therapy of gastric cancer induced by N-ethyl-N'-nitro-N-nitrosoguanidine in dogs. Jpn. J. Cancer Res. 1999, 90: 1039-1049.
87. McNeish, I.A., Green, N.K., Gilligan, M.G., Ford, M.J., Mautner, V., Young, L.S., Kerr, D.J. and Searle, P.F., Virus directed enzymes prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther. 1998, 5: 1061-1069.
88. Melief, C.J., Toes, R.E., Medema, J.P., van der Burg, S.H., Ossendorp, F. and Offringa, R., Strategies for immunotherapy of cancer. Adv. Immunol. 2000, 75: 235-282.
89. Mesnil, M. and Yamasaki, H., Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 2000, 60: 3989-3999.
90. Miyake, H., Tolcher, A. and Gleave, M.E., Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J. Natl. Cancer Inst. 2000, 92: 34-41.
91. Miyao, Y., Shimizu, K., Tamura, M., Akita, H., Ikeda, K., Mabuchi., E., Kishima, H., Hayakawa, T. and Ikenaka, K., Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: myelin basic protein promoter is strongly active in human malignant glioma cells. Jpn. J. Cancer Res. 1997, 88: 678-686.
92. Modlich, U., Pugh, C.W. and Bicknell, R., Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther. 2000, 7: 896-902.
93. Moolten, F.L., Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986, 46: 5276-5281.
94. Mroz, P.J. and Moolten, F.L., Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication. Hum. Gene Ther. 1993, 4: 589-595.
95. Mullen, C.A., Kilstrup, M. and Blaese, R.M., Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-FU: a negative selection system. Proc. Natl. Acad. Sci. USA 1992, 89: 33-37.
96. Nabel, G.J., Gordon, D., Bishop, D.K., Nickoloff, B.J., Yang, Z.Y., Aruga, A., Cameron, M.J., Nabel, E.G. and Chang, A.E., Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA liposome complexes. Proc. Natl. Acad. Sci. USA 1996, 93: 15388-15393.
97. Nagayama, Y., Nishihara, E., Iitaka, M., Namba, H., Yamashita, S. and Niwa, M., Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res. 1999, 59: 3049-3052.
98. Nakamura Y., Isolation of p53-target genes and their functional analysis. Cancer Sci. 2004, 95: 7-11.
99. Nemunaitis, J., Bohart, C., Fong, T., Meyer, W., Edelman, G., Paulson, R.S., Orr, D., Jain, V., O'Brien, J., Kuhn, J., Kowal, K.J., Burkeholder, S., Bruce, J., Ognoskie, N., Wynne, D., Martineau, D. and Ando, D., Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma. Cancer Gene Ther. 1998, 5: 292-300.
100. Nemunaitis, J., Fong, T., Robbins, J.M., Edelman, G., Edwards, W., Paulson, R.S., Bruce, J., Ognoskie, N., Wynne, D., Pike, M., Kowal, K., Merritt, J. and Ando, D., Phase I trial of interferon-gamma (TFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Ther. 1999, 6: 322-330.
101. Nemunaitis, J., Fong, T., Burrows, F., Bruce, J., Peters, G., Ognoskie, N., Meyer, W., Wynne, D., Kerr, R., Pippen, J., Oldham, F. and Ando, D., Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma. Hum Gene Ther. 1999, 10: 1289-1298.
102. O'Reilly, M.S., Holmgren, L., Chen, C. and Folkman, J., Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 1996, 2: 689-692.
103. Ohashi, M., Kanai, F., Tanaka, T., Lan, K.H., Shiratori, Y., Komatsu, Y., Kawabe, T., Yoshida, H., Hamada, H. and Omata, M., In vivo adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing pancreatic cancer. Jpn. J. Cancer Res. 1998, 89: 457-462.
104. Osaki, T., Tanio, Y., Tachibana, I., Hosoe, S., Kumagai, T., Kawase, I., Oikawa, S. and Kishimoto, T., Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 1994, 54: 5258-5261.
105. Packer, R.J., Raffel, C., Villablanca, J.G., Tonn, J.C., Burdach, S.E., Burger, K., LaFond, D., McComb, J.G., Cogen, P.H., Vezina, G. and Kapcala, L.P., Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J. Neurosurg. 2000, 92: 249-254.
106. Palmer, K., Moore, J., Everard, M., Harris, J.D., Rodgers, S., Rees, R.C., Murray, A.K., Mascari, R., Kirkwood, J., Riches, P.G., Fisher, C., Thomas, J.M., Harries, M., Johnston, S.R.D., Collins, M.K.L. and Gore, M.E., Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum. Gene Ther. 1999, 10: 1261-1268.
107. Pandha, H.S., Martin, L.A., Rigg, A., Hurst, H.C., Stamp, G.W., Sikora, K. and Lemoine, N.R., Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J. Clin. Oncol. 1999, 17: 2180-2189.
108. Park, K., Young Seol, J., Yoo, C.G., Kim, Y.W., Han, S.K., Lee, E.H., Kim, C.M., Shim, Y.S. and Lee, C.T., Adenovirus expressing p27 (Kip1) induces growth arrest of lung cancer cell lines and suppresses the growth of established lung cancer xenografts. Lung Cancer 2001, 31: 149-155.
109. Park, H.S., Cheon, J., Cho, H.Y., Ko, Y.H., Bae, J.H., Moon, D.G. and Kim, J.J., In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia. Gene Ther. 2003, 10: 1129-1134.
110. Pataer, A., Fang, B.L., Yu, R., Kagawa, S., Hunt, K.K., McDonnell, T.J., Roth, J.A. and Swisher, S.G., Adenoviral Bak overexpression mediates caspase-dependent tumor killing. Cancer Res. 2000, 60: 788-792.
111. Patterson, A.V., Zhang, H., Moghaddam, A., Bicknell, R., Talbot, D.C., Stratford, I.J. and Harris, A.L., Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br. J. Cancer 1995, 72: 669-675.
112. Phelan, A., Elliott, G. and O'Hare, P., Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat. Biotechnol. 1988, 16: 440-443.
113. Pope, I.M., Poston, G.J. and Kinsella, A.R., The role of the bystander effect in suicide gene therapy. Eur. J. Cancer 1997, 33: 1005-1016.
114. Puhlmann, M., Gnant, M., Brown, C.K., Alexander, H.R. and Bartlett, D.L., Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum. Gene Ther. 1999, 10: 649-657.
115. Ram, Z., Culver, W.K., Walbridge, S., Blaese, R.M. and Oldfield, E.H., In situ retroviral mediated gene transfer for the treatment of brain tumours in rats. Cancer Res. 1993, 53: 83-88.
116. Ren, H., Boulikas, T., Lundstrom, K., Soling, A., Warnke, P.C. and Rainov, N.G., Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene-a phase I/II clinical protocol. J. Neurooncol. 2003, 64: 147-154.
117. Rini, B.I., Selk, L.M. and Vogelzang, N.J., Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin. Cancer Res. 1999, 5: 2766-2772.
118. Ring, C.J., Blouin, P., Martin, L.A., Hurst, H.C. and Lemoine, N.R., Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme. Gene Ther. 1997, 4: 1045-1052.
119. Robertson, M.W., 3rd, Wang, M., Siegal, G.P., Rosenfeld, M., Ashford, R.S. 2nd, Alvarez, R.D., Garver, R.I. and Curiel, D.T., Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells. Cancer Gene Ther. 1998, 5: 331-336.
120. Rochlitz, C., Jantscheff, P., Bongartz, G., Dietrich, P.Y., Quiquerez, A.L., Schatz, C., Mehtali, M., Courtney, M., Tartour, E., Dorval, T., Fridman, W.H. and Herrmann, R., Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors. Cancer Gene Ther. 1999, 6: 271-281.
121. Roth, J.A., Nguyen, D., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., Ferson, D.Z., Hong, W.K., Komaki, R., Lee, J.J., Nesbitt, J.C., Pisters, K.M., Putnam, J.B., Schea, R., Shin, D.M., Walsh, G.L., Dolormente, M.M., Han, C.I., Martin, F.D., Yen, N., Xu, K., Stephens, L.C., McDonnell, T.J., Mukhopadhyay, T. and Cai, D., Retrovirus-mediated wild-type p53 gene transfer to tumours of patients with lung cancer. Nat. Med. 1996, 2: 985-991.
122. Rubin, J., Galanis, E., Pitot, H.C., Richardson, R.L., Burch, P.A., Charboneau, J.W., Reading, C.C., Lewis, B.D., Stahl, S., Akporiaye, E.T. and Harris, D.T., Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther. 1997, 4: 419-425.
123. Rudin, C.M., Holmlund, J., Fleming, G.F., Mani, S., Stadle,r W.M., Schumm, P., Monia, B.P., Johnston, J.F., Geary, R., Yu, R.Z., Kwoh, T.J., Dorr, F.A. and Ratain, M.J., Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin. Cancer Res. 2001, 7: 1214-1220.
124. Rudin, C.M., Kozloff, M., Hoffman, P.C., Edelman, M.J., Karnauskas, R., Tomek, R., Szeto, L. and Vokes, E.E., Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J. Clin. Oncol. 2004, 22: 1110-1117.
125. 2+ release and stable RNA degradation. Biochem. Biophys. Acta 1989, 1007: 158-166.
126. Sandmair, A.M., Loimas, S., Puranen, P., Immonen, A., Kossila, M., Puranen, M., Hurskainen, H., Tyynela, K., Turunen, M., Vanninen, R., Lehtolainen, P., Paljarvi, L., Johansson, R., Vapalahti, M. and Yla-Herttuala, S., Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. 2000, 11: 2197-2205.
127. Sauter, B.V., Martinet, O., Zhang, W.J., Mandeli, J. and Woo, S.L., Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. USA 2000, 97: 4802-4807.
128. Schalagbauer-Wadl, H., Klosner, G., Heere-Ress, E., Waltering, S., Moll, I., Wolff, K., Pehamberger, H. and Jansen, B., Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. Invest. Dermatol. 2000, 114: 725-730.
129. Scherr, M., Maurer, A.B., Klein, S., Ganser, A., Engels, J.W. and Grez, M., Effective reversal of a transformed phenotype by retrovirus-mediated transfer of ribozyme directed against mutant N-ras. Gene Ther. 1998, 5: 1227-1234.
130. Schmidt-Wolf, I.G.H., Finke, S., Trojaneck, B., Denkena, A., Lefterova, P., Schwella, N., Heuft, H.G., Prange, G., Korte, M., Takeya, M., Dorbic, T., Neubauer, A., Wittig, B. and Huhn, D., Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br. J. Cancer 1999, 81: 1009-1016.
131. Shen, L.Z., Wu, W.X., Xu, D.H., Zheng, Z.C., Liu, X.Y., Ding, Q., Hua, Y.B. and Yao, K., Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene. World J. Gastroenterol. 2002, 8: 270-275.
132. Singhal, S. and Kaiser, L.R., Cancer chemotherapy using suicide genes. Surg. Oncol. Clin. N. Am. 1998, 7: 505-536.
133. Smythe, W.R., Prodrug/drug sensitivity gene therapy: current status. Curr. Oncol. Rep. 2000, 2: 17-22.
134. Sobol, R.E., Shawler, D.L., Carson, C., Van Beveren, C., Mercola, D., Fakhrai, H., Garrett, M.A., Barone, R., Goldfarb, P., Bartholomew, R.M., Brostoff, S., Carlo, D.J., Royston, I. and Gold, D.P., Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: A phase I study. Clin. Cancer Res. 1999, 5: 2359-2365.
135. Sorscher, E.J., Peng, S., Bebok, Z., Allan, P.W., Bennett, L.L. and Parker, W.B. Jr., Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther. 1994, 1: 233-238.
136. Steiner, M.S., Anthony, C.T., Lu, Y. and Holt, J.T., Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum. Gene Ther. 1998, 9: 747-755.
137. Sterman, D.H., Treat, J., Litzky, L.A., Amin, K,M., Coonrod, L., Molnar-Kimber, K., Recio, A., Knox, L., Wilson, J.M., Albelda, S.M. and Kaiser, L.R., Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 1998, 9: 1083-1092.
138. Stewart, A.K., Lassam, N.J., Quirt, I.C., Bailey, D.J., Rotstein, L.E., Krajden, M., Dessureault, S., Gallinger, S., Cappe, D., Wan, Y., Addison, C.L., Moen, R.C., Gauldie, J. and Graham, F.L., Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther. 1999, 6: 350-363.
139. Stockhammer, G., Brotchi, J., Leblanc, R., Bernstein, M., Schackert, G., Weber, F., Ostertag, C., Mulder, N.H., Mellstedt, H., Seiler, R., Yonekawa, Y., Twerdy, K., Kostron, H., DeWitte, O., Lambermont, M., Velu, T., Laneuville, P., Villemure, J.G., Rutka, J.T., Warnke, P., Laseur, M., Mooij, J.J.A., Boethius, J., Mariani, L., Meyer, M., Brandli, C., Frei, K., Konu, D. and Gianella-Borradori, A., Gene therapy for glioblastome multiforme: In vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. J. Mol. Med. 1997, 75: 300-304.
140. Su, H., Lu, R., Chang, J.C. and Kan, Y.W., Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice. Proc. Natl. Acad. Sci. USA 1997, 94: 13891-13896.
141. Sun, Y., Jurgovsky, K., Moller, P., Alijagic, S., Dorbic, T., Georgieva, J., Wittig, B. and Schadendorf, D., Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther. 1998, 5: 481-490.
142. Suzuki, T., Anderegg, B., Ohkawa, T., Irie, A., Engebraaten, O., Halks-Miller, M., Holm, P.S., Curiel, D.T., Kashani-Sabet, M. and Scanlon, K.J., Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. Gene Ther. 2000, 7: 241-248.
143. Swisher, S.G., Roth, J.A., Nemunaitis, J., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., Connors, D.G., El-Naggar, A.K., Fossella, F., Glisson, B.S., Hong, W.K., Khuri, F.R., Kurie, J.M., Lee, J.J., Lee, J.S., Mack, M., Merritt, J.A., Nguyen, D.M., Nesbitt, J.C., Perez-Soler, R., Pisters, K.M., Putnam, J.B. Jr, Richli, W.R., Savin, M. and Waugh, M.K., Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 1999, 91: 763-71.
144. Tait, D.L., Obermiller, P.S., Hatmaker, A.R., Redlin-Frazier, S. and Holt, J.T., Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. Clin. Cancer Res. 1999, 5: 1708-1714.
145. Tamiya, T., Ono, Y., Wei, M.X., Mroz, P.J., Moolten, F.L. and Chiocca, E.A., Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. Cancer Gene Ther. 1996, 3: 155-162.
146. Tanaka, T., Kanai, F., Okabe, S., Yoshida, Y., Wakimoto, H., Hamada, H., Shiratori, Y., Lan, K.H., Ishitobi, M. and Omata, M., Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res. 1996, 56: 1341-1345.
147. Taneja, S.S., Pang, S., Cohan, P. and Belldegrun, A., Gene therapy: principles and potential. Cancer Surv. 1995, 23: 247-266.
148. Tepper, R.I. and Mule, J.J., Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 1994, 5: 153-164.
149. Trask, T.W., Trask, R.P., Aguilar-Cordova, E., Shine, H.D., Wyde, P.R., Goodman, J.C., Hamilton, W.J., Rojas-Martinez, A., Chen, S.H., Woo, S.L.C. and Grossman, R.G., Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. 2000, 1: 195-203.
150. Tsihlias, J., Kapusta, L. and Slingerland, J., The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Ann. Rev. Med. 1999, 50: 401-423.
151. Tsuchida, T., Kijima, H., Hori, S., Oshika, Y., Tokunaga, T., Kawai, K., Yamazaki, H., Ueyama, Y., Scanlon, K.J., Tamaoki, N. and Nakamura, M., Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma. Cancer Gene Ther. 2000, 7: 373-383.
152. Uch, R., Gerolami, R., Faivre, J., Hardwigsen, J., Mathieu, S., Mannoni, P. and Bagnis, C., Hepatoma cell-specific ganciclovir-mediated toxicity of a lentivirally transduced HSV-TkEGFP fusion protein gene placed under the control of rat alpha-fetoprotein gene regulatory sequences. Cancer Gene Ther. 2003, 10: 689-695.
153. Vandier, D., Rixe, O., Brenner, M., Gouyette, A. and Besnard, F., Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene. Cancer Res. 1998, 58: 4577-4580.
154. Vile, R.G., Nelson, J.A., Castleden, S., Chong, H. and Hart, I.R., Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 1994, 54: 6228-6234.
155. Waters, J.S., Webb, A., Cunningham, D., Clarke, P.A., Raynaud, F., di Stefano, F. and Cotter, F.E., Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 2000, 18: 1812-1823.
156. Webb, A., Cunningham, D., Cotter, F., Clarke, P.A., di Stefano, F., Ross, P., Corbo, M. and Dziewanowska, Z., BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997, 349: 1137-1141.
157. Weill, D., Mack, M., Roth, J., Swisher, S., Proksch, S., Merritt, J. and Nemunaitis, J., Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest 2000, 118: 966-70.
158. Wildner, O., Blaese, R.M. and Morris, J.C., Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 1999, 59: 410-413.
159. Xu, L., Pirollo, K.F., Tang, W.H., Rait, A. and Chang, E.H., Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum. Gene Ther. 1999, 10: 2941-2952.
160. Yoshioka, T., Wada, T., Uchida, N., Maki, H., Yoshida, H., Ide, N., Kasai, H., Hojo, K., Shono, K., Maekawa, R., Yagi, S., Hoffman, R.M. and Sugita, K., Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res. 1998, 58: 2583-2587.
161. Yuen, A.R., Halsey, J., Fisher, G.A., Holmlund, J.T., Geary, R.S., Kwoh, T.J., Dor, A. and Sikic, B.I., Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/GP 64128A) in patients with cancer. Clin. Cancer Res. 1999, 5: 3357-3363.
162. Zhang, Y., Nemunaitis, J., Scanlon, K.J. and Tong, A.W., Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice. Gene Ther. 2000, 7: 2041-2050.
163. Zhuang, S.M., Shvarts, A., Ormondt, H.V., Jochemsen, A.G., Vandereb, A.J. and Noteborn, M.H.M., Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res. 1995, 55: 486-489.